New data find gastric contents after fasting aren't higher than nondiabetics, but an expert endocrinologist disputes that conclusion and GLP-1 agonists further complicate the picture.
Studies suggest that lower stroke risk associated with newer antidiabetic therapies is not due to the drugs' tighter glycemic control. So, what is the mechanism?
Results of the STEP 9 study in people with knee OA and obesity show that semaglutide not only induced significant weight loss but also improved knee pain and physical function.
The update included background on the relationship between GLP-1 receptor agonists and endoscopic procedures, followed by clinical strategies for patients taking these medications.